Mohammed Dar, formerly of AstraZeneca Plc, has joined the UK biotech Immunocore Ltd as chief medical officer and head of clinical development to manage the company’s portfolio of T cell receptor therapies. At AstraZeneca, he led clinical development in oncology at the company’s MedImmune unit including trials supporting the approval of the checkpoint inhibitor durvalumab. Prior to this, he worked in early oncology drug development at GlaxoSmithKline Plc. Dr Dar received a bachelor’s degree in chemistry from the University of North Carolina at Chapel Hill and his MD and internal medicine training from Duke University School of Medicine, both in the US.
Immunocore announced the appointment on 7 May 2019.
Copyright 2019 Evernow Publishing Ltd.